Autopsy report · NCT01296555

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

“The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 10 years 3 months before it stopped.
• 674 participants enrolled.
• Results were posted on the registry 3 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Genentech, Inc.

Sponsor type

Industry

Conditions

Solid Cancers; Non-Hodgkin's Lymphoma

Interventions

Fulvestrant; GDC-0032; Letrozole; Midazolam

Participants

674

Sites

31

Countries

Canada, France, Spain, United States

Trials that died the same way

• The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
  “The Sponsor has discontinued the development of tesetaxel” (63% match in meaning)
• Magnetic Muscle Stimulation of Abdominal Muscle
  “Sponsor Discontinued due to business decision.” (59% match in meaning)
• RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
  “The sponsor's clinical program for the agent used in this study was discontinued.” (58% match in meaning)
• Evaluation of the Efficacy and Safety of Fentanyl Delivered by Adhesive Skin Patch in Out-Patients With Chronic Cancer Pain
  “Sponsor discontinued the study following the discovery of a number of incompletely sealed batches that were unusable.” (57% match in meaning)
• KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
  “Study discontinued due to sponsor decision.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.